AstraZeneca's Tezspire improves eosinophilic esophagitis symptoms in Phase III trial
AZN•AstraZeneca and Amgen said Tezspire met the main goals of the Phase III CROSSING trial, improving swallowing symptoms and tissue inflammation versus placebo. Benefits persisted through one year, and AstraZeneca plans to share the findings with regulators.
1. Trial results
Tezspire met the Phase III CROSSING trial’s main goals in eosinophilic esophagitis, improving swallowing symptoms and tissue inflammation versus placebo. Benefits persisted through one year, treatment cleared visible signs of disease in some patients, and the safety profile was consistent with existing indications. Results were presented at United European Gastroenterology Week 2026 in Barcelona.
